secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2022-06-09T23:59:59+00:00
Accession:  0001193125-22-171026
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics reports 2022 annual meeting vote results
-------------------------------------------------------------

- Elected Kate Haviland, Katina Dorton, Robert Gould as Class III directors for three-year term ending 2025.
- Director vote results: Haviland 25,135,506 for / 5,600,007 withheld; Dorton 27,146,569 for / 3,588,944 withheld; Gould 26,665,833 for / 4,069,680 withheld.
- Ratified Ernst & Young LLP as independent auditor for FY2022: 34,538,061 for, 20,325 against, 10,946 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522171026/0001193125-22-171026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522171026/d334925d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-171026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer